Terns Pharmaceuticals Faces Stock Market Challenges Terns Pharmaceuticals' stock recently hit a 52-week low, trading at $3.27. This marks a 54% drop from its peak of $11.40. Despite the downturn, analysts suggest potential for rebound due to oversold conditions. The company remains financially strong, with $372.8 million in reserves, funding operations into 2028.12